Hosted on MSN8mon
For Advanced Bladder Cancer, The Drug Balversa Is Now FDA Approved– A Promising Therapy For People With Specific Mutations
The U.S. Food and Drug Administration (FDA) has now approved ... FGFR3 and FGFR2. FGFR stands for fibroblast growth factor receptors. These are proteins that give cells their orders to grow ...
pharmaphorum2d
BMS gets FDA OK for first LAG-3 checkpoint inhibitor
Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its ... a negative regulator of T cells, suppressing their activity against cancer cells, so when that brake ...
pharmaphorum5y
J&J gets US okay for first targeted bladder cancer drug
Johnson & Johnson’s Balversa has become the first targeted therapy for bladder cancer after an FDA approval ... in the FGFR gene. Balversa (erdafitinib) – an FGFR inhibitor – is the first ...
Medical Xpress1mon
FDA approves Hympavzi for hemophilia
The U.S. Food and Drug Administration (FDA ... factor pathway inhibitor, thus increasing the amount of thrombin, an enzyme that is critical in blood clotting. The approval is based on an open ...
Yahoo1mon
FDA approves first once-weekly drug treatment regimen for hemophilia
Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved ... their quality of life and limiting their ability to participate in a variety of jobs, activities ...
Yahoo Finance1mon
Global LAG 3 Antibody FDA Approval Clinical Trials LAG 3 Inhibitors Market Future Growth Opportunity Insight
With the emergence of advanced PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors ... milestone in cancer treatment. The approval of Opdualag by the FDA, alongside endorsements from regulatory ...
Yahoo Finance1mon
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with ...
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies - - First child with achondroplasia expected to be dosed in Q1 2025 ...
Business Wire1mon
TheracosBio Partners with PBA Health to Provide Affordably Priced FDA-approved Diabetes Medication to Thousands of Independent Community Pharmacies
MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio today announced that BRENZAVVY® (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 ...